Katrine Bosley appointed to Galapagos’ Board of Directors Mechelen, Belgium; 4 March 2013 – Galapagos NV (Euronext: GLPG) announced today the appointment of Katrine Bosley to its Board of Directors as an independent Dr. Brus was already a member of the Galapagos Board of Directors from 2000 until Galapagos’ IPO in May 2005. The Chairman is a non-executive director and does not hold the office of CEO. His background also includes software and database development at Isis Pharmaceuticals. We are pleased to announce that Bob Rajan has joined the board of directors of Galapagos Holding S.A. as an additional independent non-executive director, effective as … Galapagos NV (Euronext&NASDAQ: GLPG) announced the appointment of Dr. Christine Mummery to its Board of Directors as an independent non-executive director. Dr. Cautreels, who had previously served as an independent director, no longer met the independence criteria upon his reappointment for a fourth consecutive term on 24 April 2018 because article 526ter, 2° of the Belgian Companies Code only allows for a maximum of three consecutive terms for independent directors. Dr. Paul Salaman poses with a land iguana in Galapagos. Galapagos Conservancy is led by a volunteer Board of Directors who bring a wide variety of expertise and enthusiasm to GC. Prior to joining Plan, Dr. San Martin was Group Vice President for Abt Associates, overseeing all the technical assistance, policy research and strategic business consulting provided by Abt Associates to its clients overseas. Billy Campbell has served as the Managing Director of Royal Caribbean’s GoBe E-Commerce venture since 2016 following a four-year tenure as CEO of Forbes Travel Guide. She has also held senior positions in the World Bank Group. The other meeting in the presence of a notary was attended by Mr. Van de Stolpe and Dr. Cautreels; all other directors were represented by proxy. Prior to joining Editas, she was the Entrepreneur-in-Residence at The Broad Institute from 2013 to 2014. Galapagos' Board of Directors has appointed Dr. Mummery to fill the vacancy that has arisen on the Board as a result of the resignation of Dr. Vicky Sato on 31 December 2014. Show your support and help us fund vital conservation efforts to protect endangered species in Galapagos. Galapagos' Board of... | April 30, 2021 Ms. Bosley also serves as chairman of the board of Arrakis Therapeutics. Learn more about each below. Mr. Lea comes from an asset management background having been an officer, director and partner of companies in the alternative asset arena, managing asset in venture capital, hedge fund, hedge fund-of-funds and private equity vehicles. Mr. Johnson is an experienced international business advisory consultant and attorney. Galapagos Conservancy Announces New President. She was a postdoctoral fellow from 1981 to 1984 at the Hubrecht Institute in Utrecht, where she later also served as a staff scientist and group leader until 2008. Galapagos NV’s board of directors consists She has a Ph.D. in Political Economy and Government from Harvard University. Mr. Lea holds a Bachelor of Science in Finance, Management and Meteorology from the University of North Carolina at Asheville and currently resides in Curaçao in the Dutch Antilles. Before joining Goldman Sachs, he was a corporate lawyer with the law firm Sullivan & Cromwell LLP. He has served on numerous not-for-profit and corporate board boards of private companies in the Caribbean Basin and broader Latin America, where he travels extensively on an ongoing basis. He lives in Cincinnati, Ohio. Dr. Sherman lives in Lafayette, California. He currently serves as a member of the Board of Managers of Paradigm Spine LLC. Mary Kerr, Ph.D., is Chief Executive Officer of NeRRe Therapeutics, and member of the supervisory board (nonexecutive director) of Galapagos NV since 26 July 2016. He received his medical degree from Cornell University Medical College. Dr. Cautreels was the President and Chief Executive Officer and member of the board of Selecta Biosciences, Inc. from 2010 until December 2018. Except for Mr. Van de Stolpe, all board members are non-executive directors. The nomination and remuneration committee nominates, for the approval of the board, candidates to fill vacancies and advises on proposals for appointment originating from shareholders, in each case taking into account Galapagos’ needs and the selection criteria determined by the board. She is a review committee member of the European Research Council, the Leducq Foundation, the Wellcome Trust (ad hoc) and the Heineken Jury Prize (KNAW). Howard Rowe, JD has served as a member of our board of directors since 2010. jldebakey@galapagos.org Director of Operations Melissa Combs mc@galapagos.org Membership Services Coordinator Diana Fulchiron dfulchiron@galapagos.org Galapagos Ambassadors Manager Alyson Wells awalty@galapagos.org Foundation Development Manager/ Office Manager Kelly Wilmeth kjones@galapagos.org Board of Directors Chairman Dr. David … Galapagos’ Board of Directors has appointed Dr. Mummery to fill the vacancy that has arisen on Galapagos listed on the US NASDAQ (ticker symbol: GLPG) in May 2015. Galapagos NV, Board of Directors, Special Report (Article 583 BCC), Warrant Plan 2010, 26 March 2010 P. 5/10 1. In 2007, she was a Radcliffe fellow at the Harvard Stem Cell Institute and Massachusetts General Hospital when human-induced pluripotent stem cells were being developed, and she was the first to derive these from patients in the Netherlands. He is a co-founder and board member of Accoy Pharmaceuticals since 2016. She was also Executive President of the Quito Zoo. He received his MA in Biochemistry and DPhil in Molecular Medicine from the University of Oxford, where he has also been a Senior Research Fellow and Professor. Dr. Charles Knapp. October 1, 2020. A formal evaluation of the board and its committees was initiated in December 2017 and was completed in March 2018. Dr. San Martin is active and holds leadership positions in a number of non-profit and for profit boards and advisory councils. She has spent the majority of her career on the R&D commercial interface in global strategy and regional operational roles, predominantly in the specialty and orphan space. A dedicated conservationist, she has been a founding member and Board member of various international conservation organizations, including Fundación Natura where she was the president of the board of directors. Rajesh Parekh, MA, DPhil has served as the Chairman of our board of directors since 2004. Dr. Parekh currently serves as a member of the board of directors of Advent Venture Partners; Advent Life Sciences LLP; Aleta, Inc.; Amphista Therapeutics Ltd.; Arrakis, Inc.; Artax, Inc.; Capella BioSciences Ltd.; Levicept Limited; PE Limited; Alpha Anomeric SA; Macrolide, Inc.; Project Paradise Limited; and Tridek-One Therapeutics SAS. He is Vice President of Conservation Research at Shedd Aquarium and has been conducting research in the wider Caribbean for 25 years. in Physics, Electronics, and Mathematics at the University of Nottingham and her Ph.D. in BioPhysics at London University in the United Kingdom. Dr. Kerr was a founding member and on the Corporate Executive team of ViiV Healthcare where she led a turnaround in the performance of the HIV business in Europe. The Board of Directors of Galapagos Conservancy, Inc. (“Galapagos Conservancy” or “GC”) announces the appointment of Dr. Paul Salaman as President of GC following the retirement of its former President and founder, Johannah Barry. Dr. Sherman joined the Board in 2012 and, following his initial term, re-joined in 2019. In view of Galapagos' listing on Euronext Amsterdam and Euronext Brussels, Galapagos' Board has changed in composition. Ms. Bosley served as the President, Chief Executive Officer and member of the board of directors of Editas Medicine, Inc. from June 2014 to March 2019. Galapagos' Board of Directors has appointed Dr. Mummery to fill the vacancy In 2018, the following persons were members of the board: Dr. Parekh (Chairman), Mr. Van de Stolpe (CEO), Dr. Van Barlingen (until 24 April 2018), Dr. Cautreels, Mr. Rowe, Ms. Bosley, Dr. Mummery and Dr. Kerr; the latter four directors were appointed as independent directors within the meaning of article 526ter of the Belgian Companies Code. Mary Kerr, Ph.D., has served as a member of our board of directors since 26 July 2016. During that time he served on the boards of EUSA Pharma (Europe) Limited, Healthcare Brands International Limited, SmallBone Innovations, Inc., MedAvante, Inc. and Ikonisys, Inc. In 2018, the board of directors held four regular meetings, eight meetings by telephone conference to discuss specific matters and two meetings in the presence of a notary (relating to the issuance of Warrant Plan 2018 and Warrant Plan 2018 RMV, and the issuance of shares with cancellation of the shareholders’ preferential subscription rights). Ms. Carolina Jijon is the director of the Quito Botanical Gardens, a position she has held since 2004 and she concurrently holds the position of Executive Director of the Botanical Foundation of the Andes. Dr. San Martin joined the Board in 2019. BASE AND PURPOSE The Board of Directors of GALAPAGOS NV (hereinafter referred to as “the Company”) has approved the present Warrant Plan 2010 by resolution of 26 March 2010 (and notary deed of 27 April 2010). She is further on the scientific advisory boards of the Gurdon Institute (Cambridge, UK), Stem Cell Australia and the Allen Institute, Seattle. During its meetings in 2018, the board dealt with matters pertaining to, among other things, our strategy and growth, the evaluation of business development opportunities, convening of the shareholders' meeting and preparation of resolutions to be submitted for approval to the shareholders, review and approval of our financial reporting and assessment of the board and its committees. Galapagos Conservancy, Inc.® is a registered 501(c)(3) non-profit organization with EIN Tax ID # 13-3281486. Galapagos NV (NASDAQ:GLPG) Q1 ... Onno van de Stolpe-- Chief Executive Officer and Member of Board of Directors. During 2018, Galapagos NV complied with the Law of 28 July 2011 with respect to gender diversification in the board of directors, and the board will continue to monitor future compliance. In 2019, Galapagos entered into a transformative 10-year global research and development collaboration with Gilead. Galapagos NV’s board of directors consists He received his Bachelor of Science degree in Zoology (1991) from Southern Illinois University, and his Master of Science (1999) and Ph.D. (2005) in Wildlife Ecology and Conservation from the University of Florida. The results were presented on an aggregate basis by the secretary of the board and served as a basis for discussion by the full board. Dr. Lane’s published research areas and expertise include systems and aquatic ecology, watershed hydrology, biogeochemistry, remote sensing, and geospatial analyses. On behalf of the board of directors, Onno van de Stolpe CEO Raj Parekh Chairman of the board of directors THE GALAPAGOS GROUP 10 Galapagos NV • H1 Report 2019 Dr. Mummery obtained her B.S. MECHELEN, BELGIUM--(Marketwire - April 01, 2011) - Galapagos NV (Euronext: GLPG) announced today that it will propose the appointment of Dr Vicki Sato to its Board of Directors at its Annual General Shareholders' Meeting on 26 April 2011. Dr. Parekh is a General Partner at Advent Life Sciences LLP, which he joined in 2006. Previously she served as Grassroots Director for the Chesapeake Bay Foundation, coordinating all the CBF’s citizen involvement and as Assistant State Naturalist for the State of Vermont. She currently serves on the boards of Genocea Biosciences, Inc., the Biotechnology Innovation Organization and of the Massachusetts Eye and Ear Institute. In proposing candidates, particular consideration is given to diversity in gender, age, nationality, educational and professional background, as well as complementary skills, knowledge and experience. His most recent roles at Goldman Sachs were as part of the European Special Situations and Principal Strategies teams where he established and led the private healthcare investing effort. Before joining Abt Associates, Dr. San Martin was Partner in charge of PricewaterhouseCoopers’ (PwC) International Financing Institutions (IFI) practice. It’s been 15 years since Emma founded AB to introduce humane cat/dog population management to the Galapagos, in order to end the use of poison for this end. Mechelen, Belgium; 23 June 2016 - Galapagos NV has the honor to invite its Shareholders, Warrant Holders, Directors and Statutory Auditor to its Special and Extraordinary... | April 8, 2021 Mr. Johnson joined the Board in 2014. Mechelen, Belgium; 1 April 2011 - Galapagos NV (Euronext: GLPG) announced today that it will propose the appointment of Dr Vicki Sato to its Board of Directors at its Annual General Shareholders' Meeting on 26 April 2011. *In 2010, Galapagos Conservancy’s Board of Directors approved a change in the organization’s fiscal year from January 1 – December 31 to April 1 – March 31. When a position on the board becomes vacant, the other directors may temporarily fill the mandate until the shareholders’ meeting appoints a new director. Lori Ulrich joined Galapagos Conservancy in 2006 with a role in communications, then production, and is now the Director of Membership and Marketing. One meeting in the presence of a notary was attended by Dr. Cautreels and Dr. Van Barlingen via telephone conference; all other directors were represented by proxy. Photo © Jessica Haverstick. Prior to earning his graduate degrees, he worked as an interpretive park ranger in the Great Smoky Mountains National Park and at the Statue of Liberty National Monument, as well as serving as assistant to the President of the Sierra Club. Dr Vicki Sato to be appointed to Galapagos ’ Board of Directors . He is Senior Research Scientist with the US federal government who has been leading and conducting ecological research for over 15 years. He received his Bachelor of Arts degree in Economics (1995) from the University of North Carolina at Chapel Hill, and his Master of Science (2000) and Ph.D. (2003) in Systems Ecology from the University of Florida. Dr. Charles Lane joined the Board in 2018. Mr. Lea joined the Board in 2019. Other endeavors have included working in the Antarctic since 1990 as expedition leader on various vessels and since the early 1990s he has been a research associate of Oceanites, which runs the Antarctic Site Inventory. As Director of the Botanical Gardens, she rebuilt and opened to the public the first Botanical garden in the city of Quito and created it as a primary reference facility for ex-situ conservation of plants. Kicker Rock from Cerro Brujo, San Cristóbal. Dr. Kerr, a UK national, is Chief Executive Officer and director at NeRRe Therapeutics and Chief Executive Officer and director at KaNDy Therapeutics. Mr. Polatty joined the Board in 2016. His current work is in healthcare delivery reform. Using iguanas as model organisms, his research focuses primarily on understanding the effects of anthropogenic disturbance on endangered taxa and designing conservation strategies to prevent further population declines and habitat degradation. She served on the Ethical Councils of the Dutch Ministry of Health, is member of the Royal Netherlands Academy of Arts and Sciences (KNAW), the KHMW, editor of the Cell Press journal Stem Cell Reports, (vice) president of the International Society for Stem Cell Research and past-president of the International Society of Differentiation. Furthermore, our board members have different educational backgrounds, as can be read in each of their profiles (above). She served on the Board of the UVM Rubenstein School of Environmental and Natural Resources for 19 years, 11 as Chair. During an academic career at Oxford University, he co-founded Oxford GlycoSciences PLC, where he served as Chief Scientific Officer and Chief Executive Officer from 1988 until its sale to Celltech Group PLC (now UCB SA) in 2003. Lori played a large role in helping the organization establish a solid digital presence though its website, email communications, and online engagement, while staying current through rapidly changing online trends over the … Prior to joining Hayfin Capital Management, he was a Managing Director with The Goldman Sachs Group, Inc. where he had multiple healthcare responsibilities over his 12 years at the firm. In 2018, the board thus consisted of three women and five men (as from 24 April 2018: four men), representing four different nationalities and different age categories. He also was a Conservation Research Postdoctoral Fellow (2010) with the Institute for Conservation Research at the San Diego Zoo. Galapagos' Board of Directors has appointed Dr. Mummery to fill the vacancy that has arisen on the Board as a result of the resignation of Dr. Vicky Sato on 31 December 2014. He graduated from the University of Antwerp, with a Doctorate in Chemistry, specializing in mass spectrometry. In 2002, she became a Professor at the Utrecht University Medical Centre in the Netherlands. While living in Washington, DC he served on the Board of Trustees for the National Symphony Orchestra and the Imagination Stage. Prior to joining Solvay he was employed by Sanofi SA, Sterling Winthrop, Inc. and Nycomed Amersham PLC in a variety of R&D management positions in Europe and in the United States from 1979 to 1998. This evaluation specifically addressed the functioning of the board, the size and composition of the board, the interaction between the board and the executive management, and the functioning of the audit committee and the nomination and remuneration committee. Her primary research focus is currently the development and use of stem cells in cardiovascular development and disease. Mr. Polatty lives on the island of Santa Cruz, Galapagos and Tumbaco, Ecuador. Galapagos Announces Changes to Board of Directors Tuesday May 24, 2:06 am ET MECHELEN, Belgium, May 24, 2005 (PRIMEZONE) -- Galapagos NV, a genomics-based drug discovery company, announces changes to its Board of Directors. Mary Kerr, Ph.D. - Non-Executive Independent Director. Dr. Kerr gained a Ph.D. in Pharmacology at the University of Bradford, did post-doctoral research at the Michigan Cancer Foundation in Detroit and has an MBA from the University of Kingston. Mr. Bradley T. Johnson, Chair. She was responsible for leading the rapid growth of the unit (doubling it in size in less than 3 years) and led the company’s first acquisition. Galapagos NV, Board of Directors, Special Report (Article 596 BCC). As of 2008, Dr. Christine Mummery is Professor of Developmental Biology and Chair of the Department of Anatomy and Embryology at the Leiden University Medical Centre (LUMC) in … Each of the directors’ expertise and experience is exemplified by the varied professional activities they carry out and offices they hold. He holds a medical degree from the University of Groningen. MECHELEN, BELGIUM--(Marketwire - March 04, 2013) - Galapagos NV (Euronext: GLPG) announced today the appointment of Katrine Bosley to its Board of Directors as an independent Non-Executive Director. The directors are appointed by the shareholders’ meeting upon the proposal of the board, for a renewable term of up to four years. Ms. Swanson lives in Annapolis, Maryland. in Biology. Onno van de Stolpe – Please refer to the “Composition of Galapagos NV’s executive committee” for a biography. In 2015, Galapagos signed a collaboration agreement with Gilead for the development and commercialization of filgotinib. Galapagos NV announced today the appointment of Katrine Bosley to its Board of Directors as an independent Non-Executive Director. He lives in southern Virginia. Ms. Swanson joined the Board in 2018. The board of directors acts as a collegial body. Dr. Charles Knapp joined the Board in 2020. Mechelen, Belgium; 4 November 2015 - Galapagos NV announced the appointment of Dr. Christine Mummery to its Board of Directors as an independent non-executive director. Mr. Hurdle H. “Trip” Lea, Treasurer. Mr. Rowe is Managing Director at Hayfin Capital Management LLP. The board does so by assuming the authority and responsibilities assigned to it by Belgian corporate law and by combining entrepreneurial leadership with appropriate risk assessment and management. A 20-year programming executive spanning leadership roles at broadcast and major cable networks, Campbell served as President of Discovery Networks US following his role as President of Miramax Television, where he led the production of Emmy-nominated “Project Greenlight.” A native of Greenville, SC, Campbell is a 1982 graduate of Harvard College and a 1987 graduate of the Harvard Business School (MBA). 04.06.21 April 6, 2021 This month, the largest and most-utilized evaluator of charities,... More >, 03.29.21 March 28, 2021 On the afternoon of Sunday, March 28, Galapagos National Park... More >, 03.02.21 March 2, 2021 On Friday, February 26, 191 juvenile tortoises of the Chelonoidis... More >, By Wacho Tapia, Director of the Giant Tortoise Restoration Initiative Alcedo... More >, By Lucas Bustamante, co-founder at Tropical Herping and Giant Tortoise Restoration... More >, By Linda Cayot, retired GC Science Advisor In July 2012 a mere two weeks... More >. She is trained in the sciences — as a field ecologist and wildlife biologist — with degrees from the University of Vermont and Yale University and has been honored with an Honorary Doctorate of Laws from UVM and more than a dozen local, state and regional recognitions for her conservation leadership. Ms. Bosley joined Adnexus Therapeutics from Biogen Idec, Inc. where she had roles in business development, commercial operations and portfolio strategy in the United States and Europe. Dr. Cautreels was a director of Innogenetics NV and ArQule, Inc. from 1999 until 2006, and of Seres Therapeutics Inc. from 2012 until 2016. Dr. Sherman’s experience in the pharmaceutical industry includes research at the RW Johnson Pharmaceutical Research Institute and the Salk Institute in La Jolla, California. Dr. Charles Lane, Secretary. Dr. Mette has broad experience in both academic medical centers and non-university healthcare systems as an expert in lung diseases and as a senior physician executive. Product development, regulatory approval and commercialization, Financial position and need for additional capital, Criteria and methods to evaluate performance, Gross remuneration of other executive committee members, Conflict of interests and related parties, Statements of income and comprehensive income, Notes to the consolidated financial statements, 3.

Royal Dutch Mint Lion Dollar, How Old Is Prince Harry And William, Cambridge Classics Reading List, Brei Meaning In English, Military Lego Nz, Twenty Mile House Address, New Jersey Soldiers In The Revolutionary War, Ss501 4 Chance, Ucla Office Supplies,